Akeso, Inc. (“Akeso”) is a biopharmaceutical company dedicated to the research, development, manufacture and commercialization of innovative and affordable antibody drugs for patients worldwide. Akeso was listed on the Main Board of the Hong Kong Stock Exchange (HKEX) on April 24, 2020, with the stock code “09926.” Starting in early 2024, Akeso completed two share issuances on the HKEX to expand its shareholder and capital base, strengthen its financial position, and further promote its business development.

In addition to issuing 24,800,000 shares on the HKEX in March 2024, Akeso completed another issuance of 31,700,000 shares on the HKEX in October 2024, accounting for 3.53% of Akeso’s total issued shares after the completion of the issuance. The total proceeds from this issuance are approximately HKD 1,942.58 million, which will mainly be used for the global and the China clinical development of Akseo’s core products, the development of other clinical pipeline products in oncology and immunology, and the commercialization of existing approved products, as well as for general corporate purposes. On October 15, 2024, Akeso received approval from the HKEX for the listing of the 31,700,000 newly issued shares.

Fangda Partners acted as Akeso’s PRC legal counsel and participated throughout the entire process of the overseas share issuance, including by assisting Akeso in completing the filing procedures with the China Securities Regulatory Commission. The Fangda team was led by partners Jeffrey DING and Yvette LIU. Team members included counsels HU Shuwen and FANG Yuan, as well as associate ZHENG Chunyuan.